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Abstract
Amorphous silica nanoparticles (nSP) have been used as a polishing agent and/or as a remineralization promoter
for teeth in the oral care field. The present study investigates the effects of nSP on osteoclast differentiation and
the relationship between particle size and these effects. Our results revealed that nSP exerted higher cytotoxicity in
macrophage cells compared with submicron-sized silica particles. However, tartrate-resistant acid phosphatase
(TRAP) activity and the number of osteoclast cells (TRAP-positive multinucleated cells) were not changed by nSP
treatment in the presence of receptor activator of nuclear factor B ligand (RANKL) at doses that did not induce
cytotoxicity by silica particles. These results indicated that nSP did not cause differentiation of osteoclasts.
Collectively, the results suggested that nanosilica exerts no effect on RANKL-induced osteoclast differentiation of
RAW264.7 cells, although a detailed mechanistic examination of the nSP70-mediated cytotoxic effect is needed.
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Introduction
Recently, amorphous silica nanoparticles (nSP) with a
controlled particle size below 100 nm have been a focus
of investigations in various fields of industry. nSP have
been used in a number of different industrial applica-
tions such as medicine, cosmetics and foods. In addi-
tion, the usability of nSP has been demonstrated in the
oral care field, e.g. as a polishing agent and/or as a remi-
neralization promoter for teeth [1,2]. It has been
reported that about 20% of toothpastes contain nSP.
B e c a u s en S Ph a v ea l r e a d yb e c o m ec o m m o n l yu s e d
materials, it is difficult to imagine our daily life without
them. Furthermore, given the recent use of smaller-sized
and/or well-dispersed silica particles in various fields, it
is expected that the use of these particles will increase
in the future. On the other hand, there have been many
r e p o r t st h a tn S Pe x e r tb i o l o g i c a le f f e c t st h a ta r en o t
induced by conventional silica particles [3,4], although
the reasons for the effects of particle size on biological
responses were unclear. There are growing concerns
about the safety of nSP [5]. However, current risk ana-
lyses do not yet focus sufficiently on the particle sizes.
Accordingly, there is a compelling need to clarify the
biological and cellular responses induced by different
particle sizes. To ensure the safe production and use of
nSP, it is very important to collect safety information on
them via properly designed studies, taking into consid-
eration exposure levels and cellular responses.
Our group carried out a previous study of the safety of
nSP and revealed that surface unmodified nSP could
pass though the skin barrier, migrate into the blood-
stream and circulate throughout the entire body [6].
This suggests that nSP may be absorbed through the
oral mucosa easily when nSP, including oral care pro-
ducts, are used. Furthermore, it is possible that nSP cir-
culating in the blood can reach the alveolar bone, which
is presented in the submucosal layer, as well as various
cells such as macrophages and osteoblasts. In particular,
macrophages are known as multifunctional cells, as they
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also as pre-osteoclasts [7]. Osteoclasts that resorb bone
play an important role in bone remodelling. Osteoclas-
togenesis involves complex pathways with intricate rela-
tionships between multiple signalling molecules. In
particular, receptor activator of nuclear factor B ligand
(RANKL) is known to be a key molecule that initiates
osteoclast formation [8]. In addition, reactive oxygen
species (ROS) and pro-inflammatory cytokines such as
interleukin (IL)-1, IL-6, IL-8 and tumour necrosis factor
alpha are potent stimulators of osteoclast formation and
activity [9-11]. Our studies revealed that nSP induced
high ROS and pro-inflammatory cytokine production,
and these cellular responses may induce excess osteo-
clast differentiation. Acceleration of osteoclast differen-
tiation, that is excess bone resorption, accelerates the
onset of osteoporosis, arthritis and periodontal disease
[12-14]. Therefore, we consider that it is necessary to
estimate nSP-induced effects on osteoclast differentia-
tion. Furthermore, because we indicated previously that
nSP induced different cellular responses from submi-
cron-sized silica particles, such as those described above,
it was of interest to analyse the effects of particle size on
osteoclast differentiation. Here, we investigate nSP-
induced effects on osteoclast differentiation and the
relationship between particle size and these effects.
Experimental procedures
Silica particles
Suspensions of amorphous silica particles (Micromod
Partikeltechnologie GmbH, Warnemuende, Germany)
(25 and 50 mg/ml) were used in this study; particle size
diameters were 70, 300 and 1,000 nm (designated as
nSP70, nSP300 and mSP1000, respectively). Silica parti-
cle suspensions were stored at room temperature. The
suspensions were sonicated for 5 min and then vortexed
for 1 min immediately prior to use.
Cell culture
The mouse macrophage cell line RAW264.7 was
obtained from the American Type Culture Collection
(ATCC, Manassas, VA, USA). RAW264.7 cells were cul-
tured in Dulbecco’s Modified Eagle Medium supplemen-
ted with 10% heat-inactivated fetal calf serum (FCS), 1%
antibiotic-antimycotic mix stock solution (Invitrogen
Corporation, Carlsbad, CA, USA). All cultures were
incubated at 37°C in a humidified atmosphere with 5%
CO2.
Cytotoxicity test
The cytotoxicity of silica particle-treated RAW264.7
cells and untreated cells was assessed using a WST-8
assay. Cells, 1.5 × 10
3, were cultured with varying con-
centrations of silica particles diluted with medium for 5
days at 37°C and 10 μl of Cell Count Reagent SF (Naca-
lai Tesque, Inc., Kyoto, Japan) was then added into each
well. After 1 h, absorbance was measured at 450 nm
(reference, 650 nm) using a microplate reader (Mithras
LB940; BERTHOLD TECHNOLOGIES GmbH & Co.
KG, Bald Wildbad, Germany).
TRAP staining and activity assay
Osteoclast differentiation of silica particle-treated
RAW264.7 cells was assessed by tartrate-resistant acid
phosphatase (TRAP) staining and activity. RAW264.7
cells were suspended in phenol red-free a-MEM con-
taining 10% heat-inactivated FCS, 1% antibiotic-antimy-
cotic mix stock solution. Cells numbering 2 × 10
4 per
well were cultured in 48-well plates with 10 μg/ml of
silica particles and RANKL (30 ng/ml) diluted with phe-
nol red-free medium for 5 days. TRAP staining was car-
ried out using a TRAP/alkaline phosphatase (ALP) stain
kit (Wako Pure Chemicals Industries Ltd., Osaka, Japan)
according to the protocol provided in the kit. Images of
TRAP-positive multinucleated cells (number of nuclei >
3) were captured with a microscope. To measure TRAP
activity, cells were fixed with 10% formalin for 10 min
and 95% ethanol for 1 min, and then 100 μlo fc i t r a t e
buffer (50 mM, pH 4.6) containing 10 mM sodium tar-
trate and 5 mM p-nitrophenylphosphate (Sigma-Aldrich
C o r p o r a t i o n ,S t .L o u i s ,M O ,U S A )w a sa d d e dt ot h e
wells containing fixed cells in the 48-well plates. After
incubation for 1 h, enzyme reaction mixtures in the
wells were transferred to new plates containing an equal
volume of 0.1 N NaOH. Absorbance was measured at
410 nm using a microplate reader (Mithras LB940;
BERTHOLD TECHNOLOGIES GmbH & Co. KG, Bald
Wildbad, Germany). Each experiment was performed in
triplicate.
Statistical analysis
All data are reported as the mean ± SD. The signifi-
cance of variation among different groups was deter-
mined by one-way ANOVA. Differences between the
experimental and control groups were determined using
the Bonferroni test. P < 0.05 was considered significant.
Results and discussion
This study evaluated the effects of amorphous silica par-
ticles on osteoclast differentiation of macrophage cells,
using silica particles of 70 (nSP70), 300 (nSP300) and
1,000 nm (mSP1000) in diameter. We previously con-
firmed that these silica particles were spherical, and the
primary particle sizes were approximately uniform [6].
In addition, none of the silica particles used in this
s t u d yw e r em o d i f i e dw i t ha n yf u n c t i o n a lg r o u p s ,a n d
their surfaces were nonporous. The mean particle size
in PBS suggested that the silica particles used in this
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tion, i.e. they did not aggregate [6].
To evaluate the cytotoxicity induced by silica particle
treatment of the mouse macrophage cell line RAW264.7
cells, a WST-8 cell proliferation assay was carried out.
The results showed that 30 μg/ml of nSP300 and
mSP1000 treatment for 5 days did not induce cytotoxi-
city in RAW264.7 cells. In contrast, nSP70 treatment
induced higher cytotoxicity (about 40% viability of non-
treated cells) at 30 μg/ml, although 10 μg/ml of nSP70
treatment produced only marginal cytotoxicity (Figure
1). These results indicated that decreasing the silica par-
ticle size to below 100 nm increased the cytotoxicity sig-
nificantly. We have confirmed that the number of silica
particles ingested by cells increases as the particle size
decreases, and only nSP70 invaded into the nuclei of
dendritic cells which, along with macrophages, have a
phagocytic capacity [15]. We also found that only nSP70
invaded into the nucleus, in other words the intracellu-
lar localization of nSP70 differed from that of nSP300
and mSP1000 [15]. From these results, it was suspected
that differences in the number of ingested silica particles
and/or in their intracellular localization were significant
factors in their observed cytotoxicity in RAW264.7 cells.
Results of this experiment confirmed that not all silica
particles induced cytotoxicity at 10 μg/ml in RAW264.7
cells, and therefore subsequent studies were carried out
at 10 μg/ml silica particle treatment.
In order to investigate the effects of nanosilica on
osteoclast differentiationi nR A W 2 6 4 . 7c e l l s ,T R A P
activity, which is a known indicator of osteoclast differ-
entiation, was measured. TRAP activity levels of RANKL
(which is a key molecule in osteoclast differentiation)-
treated RAW264.7 cells were significantly increased
compared to non-treated RAW264.7 cells (Figure 2). On
the other hand, TRAP activity levels of RAW264.7 cells
treated with RANKL and silica particles were almost
equal to those of cells treated with RANKL alone. An
analysis comparing TRAP activities between nSP70,
nSP300 and mSP1000 did not reveal significant size-
dependent changes (Figure 2). Furthermore, the number
of TRAP-positive multinucleated cells were tallied as a
measure of osteoclast differentiation by RANKL and
silica particle treatment. As a result of TRAP staining,
RAW264.7 cells treated by RANKL alone or by RANKL
with silica particles were almost all TRAP positive (Fig-
ure 3). The number of TRAP-positive multinucleated
cells indicated no significant differences following each
silica particle treatment, although nSP70-treated
RAW264.7 cells tended to have an increased number of
TRAP-positive multinucleated cells compared to cells
treated with RANKL alone (Figure 4). These results sug-
gested that none of the silica particle sizes used in this
study induced effects on osteoclast differentiation of
RAW264.7 cells at the doses given.
In the dentistry field, it is well-known that wear parti-
cles from materials used in implants can induce bone
destruction, and this can become a significant
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Figure 1 Effect of silica particles on cytotoxicity. The cytotoxicity
of RAW264.7 cells after incubation with nSP70, nSP300 or mSP1000
for 5 days was evaluated using the WST-8 assay. The percentage
increase in cytotoxicity was calculated relative to the negative
control. Data are expressed as the mean ± SD (n = 3). *P < 0.05, **P
< 0.01 vs non-treated.
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Figure 2 Effect of silica particles on the RANKL-induced TRAP
activity in RAW264.7 cells. RAW264.7 cells were incubated with 10
μg/ml silica particles and 30 ng/ml RANKL for 5 days. TRAP activity
was calculated relative to the negative controls (medium without
RANKL). Data are expressed as the mean ± SD (n = 3).
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implants and/or artificial bone. Some reports have sug-
gested that micro-sized particles (about 4-9 μmi nd i a -
meter) increased the expression of RANKL and/or
osteoclast differentiation-related genes in bone marrow
cells [16,17]. These reports suggested that micro-sized
particles above 4 μm accelerated the osteoclast differen-
tiation. On the other hand, in the case of nano- and
subnano-sized particles, it has been reported that parti-
cles did not affect osteoclast differentiation or the
expression of inflammatory cytokines and osteoclast dif-
ferentiation-regulated genes [18]. Our earlier results and
the present report suggest that acceleration effects of
particles on osteoclast differentiation slowed as the par-
ticles got smaller, until they reached nanosize. In other
words, the particle size is an important characteristic in
the ability of nanoparticles to induce osteoclast differen-
tiation. The mechanism by which cells take up particles
differs according to particle sizes [19]. The larger parti-
cles (from several micrometers to several dozen micro-
meters) and the smaller particles (from several dozen to
several hundred nanometers) are believed to be taken
up by macrophage cells via phagocytosis and macropi-
nocytosis, respectively [19]. Therefore, these differences
of particle uptake pathway may be one of the factors
producing the observed effect of particle size on osteo-
clast differentiation.
Collectively, the results presented here indicated that
nanosilica has no effect on osteoclast differentiation.
They also support the safety of nanosilicas that are used
in the production of highly functional materials for oral
care fields [1,20]. We believe that applications of nanosi-
lica will extend to these new fields in the near future
following further careful safety study.
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CD
Figure 3 Effect of silica particles on the RANKL-induced osteoclast differentiation in RAW264.7 cells (TRAP staining). RAW264.7 cells
were incubated with 10 μg/ml silica particles and 30 ng/ml RANKL for 5 days. Osteoclast genesis was confirmed by TRAP staining. (A) RANKL
alone (30 ng/ml), (B) nSP70 10 μg/ml with RANKL 30 ng/ml, (C) nSP300 10 μg/ml with RANKL 30 ng/ml, (D) mSP1000 10 μg/ml with RANKL 30
ng/ml. Arrows show osteoclast cells (TRAP-positive multinucleate cells (> 3 nuclei)). Magnifications of all photographs are ×400.
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Figure 4 Number of osteoclasts induced by RANKL and silica
particles in RAW264.7. RAW264.7 cells were incubated with 10 μg/
ml silica particles and 30 ng/ml RANKL for 5 days. The number of
TRAP-positive multinucleate cells (> 3 nuclei) were counted as
osteoclasts in three different areas. Data are expressed as the mean
±S D( n = 3).
Nabeshi et al. Nanoscale Research Letters 2011, 6:464
http://www.nanoscalereslett.com/content/6/1/464
Page 4 of 5Acknowledgements
This study was supported in part by Grants-in-Aid for Scientific Research
from the Ministry of Education, Culture, Sports, Science and Technology of
Japan (MEXT), and from the Japan Society for the Promotion of Science
(JSPS); and by a the Knowledge Cluster Initiative (MEXT); by Health Labour
Sciences Research Grants from the Ministry of Health, Labour and Welfare of
Japan (MHLW); by a Global Environment Research Fund from Minister of the
Environment; by Food Safety Commission (Cabinet Office); by The
Cosmetology Research Foundation; by The Smoking Research Foundation;
and by The Takeda Science Foundation.
Author details
1Laboratory of Toxicology and Safety Science, Graduate School of
Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-
0871, Japan
2Laboratory of Biopharmaceutical Research (Pharmaceutical
Proteomics), National Institute of Biomedical Innovation, 7-6-8 Saito-Asagi,
Ibaraki, Osaka 567-0085, Japan
3The Center for Advanced Medical
Engineering and Informatics, Osaka University, 1-6 Yamadaoka, Suita, Osaka
565-0871, Japan
4Laboratory of Biomedical Innovation, Graduate School of
Pharmaceutical Sciences, Osaka University, 7-6-8 Saito-Asagi, Ibaraki, Osaka,
567-0085, Japan
Authors’ contributions
HN and TY designed the study. HN, TA, TY, ST, TH, MU, KI, TY, KH and YM
performed experiments. HN and TY collected and analysed data. HN and TY
wrote the manuscript. KN, YA, HK, ST, NI and YY gave technical support and
conceptual advice. YT supervised all of the projects. All authors discussed
the results and commented on the manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 18 April 2011 Accepted: 22 July 2011 Published: 22 July 2011
References
1. Gaikwad RM, Sokolov I: Silica nanoparticles to polish tooth surfaces for
caries prevention. J Dent Res 2008, 87:980-983.
2. Liao WQ, Zang YL, Shao JZ: Sporotrichosis presenting as pyoderma
gangrenosum. Mycopathologia 1991, 116:165-168.
3. Napierska D, Thomassen LC, Lison D, Martens JA, Hoet PH: The nanosilica
hazard: another variable entity. Part Fibre Toxicol 2010, 7:39.
4. Yamashita K, Yoshioka Y, Higashisaka K, Mimura K, Morishita Y, Nozaki M,
Yoshida T, Ogura T, Nabeshi H, Nagano K, Abe Y, Kamada H, Monobe Y,
Imazawa T, Aoshima H, Shishido K, Kawai Y, Mayumi T, Tsunoda SI, Itoh N,
Yoshikawa T, Yanagihara I, Saito S, Tsutsumi Y: Nat Nanotechnol. 2011.
5. Maynard AD, Aitken RJ, Butz T, Colvin V, Donaldson K, Oberdörster G,
Philbert MA, Ryan J, Seaton A, Stone V, Tinkle SS, Tran L, Walker NJ,
Warheit DB: Safe handling of nanotechnology. Nature 2006, 444:267-269.
6. Nabeshi H, Yoshikawa T, Matsuyama K, Nakazato Y, Matsuo K, Arimori A,
Isobe M, Tochigi S, Kondoh S, Hirai T, Akase T, Yamashita T, Yamashita K,
Yoshida T, Nagano K, Abe Y, Yoshioka Y, Kamada H, Imazawa T, Itoh N,
Nakagawa S, Mayumi T, Tsunoda S, Tsutsumi Y: Systemic distribution,
nuclear entry and cytotoxicity of amorphous nanosilica following topical
application. Biomaterials 2011, 32:2713-2724.
7. Ash P, Loutit JF, Townsend KM: Osteoclasts derived from haematopoietic
stem cells. Nature 1980, 283:669-670.
8. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ:
Modulation of osteoclast differentiation and function by new members
of the tumor necrosis factor receptor and ligand families. Endocr Rev
1999, 20:345-357.
9. Dougall WC, Glaccum M, Charrier K, Rohrbach K, Brasel K, De Smedt T,
Daro E, Smith J, Tometsko ME, Maliszewski CR, Armstrong A, Shen V, Bain S,
Cosman D, Anderson D, Morrissey PJ, Peschon JJ, Schuh J: RANK is
essential for osteoclast and lymph node development. Genes Dev 1999,
13:2412-2424.
10. Wiktor-Jedrzejczak W, Bartocci A, Ferrante AW, Ahmed-Ansari A, Sell KW,
Pollard JW, Stanley ER: Total absence of colony-stimulating factor 1 in the
macrophage-deficient osteopetrotic (op/op) mouse. Proc Natl Acad Sci
USA 1990, 87:4828-4832.
11. Yoshida H, Hayashi S, Kunisada T, Ogawa M, Nishikawa S, Okamura H,
Sudo T, Shultz LD: The murine mutation osteopetrosis is in the coding
region of the macrophage colony stimulating factor gene. Nature 1990,
345:442-444.
12. Takayanagi H: Osteoimmunology: shared mechanisms and crosstalk
between the immune and bone systems. Nat Rev Immunol 2007,
7:292-304.
13. Teitelbaum SL, Ross FP: Genetic regulation of osteoclast development
and function. Nat Rev Genet 2003, 4:638-649.
14. Theill LE, Boyle WJ, Penninger JM: RANK-L and RANK: T cells, bone loss,
and mammalian evolution. Annu Rev Immunol 2002, 20:795-823.
15. Nabeshi H, Yoshikawa T, Matsuyama K, Nakazato Y, Arimori A, Isobe M,
Tochigi S, Kondoh S, Hirai T, Akase T, Yamashita T, Yamashita K, Yoshida T,
Nagano K, Abe Y, Yoshioka Y, Kamada H, Imazawa T, Itoh N, Tsunoda S,
Tsutsumi Y: Size-dependent cytotoxic effects of amorphous silica
nanoparticles on Langerhans cells. Pharmazie 2010, 65:199-201.
16. Clohisy JC, Frazier E, Hirayama T, Abu-Amer Y: RANKL is an essential
cytokine mediator of polymethylmethacrylate particle-induced
osteoclastogenesis. J Orthop Res 2003, 21:202-212.
17. Pioletti DP, Kottelat A: The influence of wear particles in the expression
of osteoclastogenesis factors by osteoblasts. Biomaterials 2004,
25:5803-5808.
18. Tautzenberger A, Kreja L, Zeller A, Lorenz S, Schrezenmeier H, Mailänder V,
Landfester K, Ignatius A: Direct and indirect effects of functionalised
fluorescence-labelled nanoparticles on human osteoclast formation and
activity. Biomaterials 2010, 32:1706-1714.
19. Hillaireau H, Couvreur P: Nanocarriers’ entry into the cell: relevance to
drug delivery. Cell Mol Life Sci 2009, 66:2873-2896.
20. Muller WE, Boreiko A, Wang X, Krasko A, Geurtsen W, Custodio MR,
Winkler T, Lukic-Bilela L, Link T, Schroder HC: Morphogenetic activity of
silica and bio-silica on the expression of genes controlling
biomineralization using SAOS-2 cells. Calcif Tissue Int 2007, 81:382-393.
doi:10.1186/1556-276X-6-464
Cite this article as: Nabeshi et al.: Effect of amorphous silica
nanoparticles on in vitro RANKL-induced osteoclast differentiation in
murine macrophages. Nanoscale Research Letters 2011 6:464.
Submit your manuscript to a 
journal and beneﬁ  t from:
7 Convenient online submission
7 Rigorous peer review
7 Immediate publication on acceptance
7 Open access: articles freely available online
7 High visibility within the ﬁ  eld
7 Retaining the copyright to your article
    Submit your next manuscript at 7 springeropen.com
Nabeshi et al. Nanoscale Research Letters 2011, 6:464
http://www.nanoscalereslett.com/content/6/1/464
Page 5 of 5